COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study
<strong>Background</strong> To date, few data on paediatric COVID-19 have been published, and most reports originate from China. This study aimed to capture key data on children and adolescents with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection across Europe to i...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2020
|
| _version_ | 1826305674559094784 |
|---|---|
| author | Götzinger, F Santiago-García, B Noguera-Julián, A Lanaspa, M Lancella, L Calò Carducci, FI Gabrovska, N Velizarova, S Prunk, P Osterman, V Krivec, U Lo Vecchio, A Shingadia, D Soriano-Arandes, A Melendo, S Lanari, M Pierantoni, L Wagner, N L'Huillier, AG Heininger, U Ritz, N Bandi, S Krajcar, N Roglić, S Santos, M Christiaens, C Creuven, M Buonsenso, D Welch, SB Bogyi, M Brinkmann, F Tebruegge, M Song, R Pfefferle, J Zacharasiewicz, A Berger, A Berger, R Strenger, V Kohlfürst, DS Zschocke, A Bernar, B Simma, B Haberlandt, E Thir, C Biebl, A Vanden Driessche, K Boiy, T Van Brusselen, D Bael, A Debulpaep, S Schelstraete, P |
| author2 | ptbnet COVID-19 Study Group |
| author_facet | ptbnet COVID-19 Study Group Götzinger, F Santiago-García, B Noguera-Julián, A Lanaspa, M Lancella, L Calò Carducci, FI Gabrovska, N Velizarova, S Prunk, P Osterman, V Krivec, U Lo Vecchio, A Shingadia, D Soriano-Arandes, A Melendo, S Lanari, M Pierantoni, L Wagner, N L'Huillier, AG Heininger, U Ritz, N Bandi, S Krajcar, N Roglić, S Santos, M Christiaens, C Creuven, M Buonsenso, D Welch, SB Bogyi, M Brinkmann, F Tebruegge, M Song, R Pfefferle, J Zacharasiewicz, A Berger, A Berger, R Strenger, V Kohlfürst, DS Zschocke, A Bernar, B Simma, B Haberlandt, E Thir, C Biebl, A Vanden Driessche, K Boiy, T Van Brusselen, D Bael, A Debulpaep, S Schelstraete, P |
| author_sort | Götzinger, F |
| collection | OXFORD |
| description | <strong>Background</strong>
To date, few data on paediatric COVID-19 have been published, and most reports originate from China. This study aimed to capture key data on children and adolescents with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection across Europe to inform physicians and health-care service planning during the ongoing pandemic.
<br>
<strong>Methods</strong>
This multicentre cohort study involved 82 participating health-care institutions across 25 European countries, using a well established research network—the Paediatric Tuberculosis Network European Trials Group (ptbnet)—that mainly comprises paediatric infectious diseases specialists and paediatric pulmonologists. We included all individuals aged 18 years or younger with confirmed SARS-CoV-2 infection, detected at any anatomical site by RT-PCR, between April 1 and April 24, 2020, during the initial peak of the European COVID-19 pandemic. We explored factors associated with need for intensive care unit (ICU) admission and initiation of drug treatment for COVID-19 using univariable analysis, and applied multivariable logistic regression with backwards stepwise analysis to further explore those factors significantly associated with ICU admission.
<br>
<strong>Findings</strong>
582 individuals with PCR-confirmed SARS-CoV-2 infection were included, with a median age of 5·0 years (IQR 0·5–12·0) and a sex ratio of 1·15 males per female. 145 (25%) had pre-existing medical conditions. 363 (62%) individuals were admitted to hospital. 48 (8%) individuals required ICU admission, 25 (4%) mechanical ventilation (median duration 7 days, IQR 2–11, range 1–34), 19 (3%) inotropic support, and one (<1%) extracorporeal membrane oxygenation. Significant risk factors for requiring ICU admission in multivariable analyses were being younger than 1 month (odds ratio 5·06, 95% CI 1·72–14·87; p=0·0035), male sex (2·12, 1·06–4·21; p=0·033), pre-existing medical conditions (3·27, 1·67–6·42; p=0·0015), and presence of lower respiratory tract infection signs or symptoms at presentation (10·46, 5·16–21·23; p<0·0001). The most frequently used drug with antiviral activity was hydroxychloroquine (40 [7%] patients), followed by remdesivir (17 [3%] patients), lopinavir–ritonavir (six [1%] patients), and oseltamivir (three [1%] patients). Immunomodulatory medication used included corticosteroids (22 [4%] patients), intravenous immunoglobulin (seven [1%] patients), tocilizumab (four [1%] patients), anakinra (three [1%] patients), and siltuximab (one [<1%] patient). Four children died (case-fatality rate 0·69%, 95% CI 0·20–1·82); at study end, the remaining 578 were alive and only 25 (4%) were still symptomatic or requiring respiratory support.
<br>
<strong>Interpretation</strong>
COVID-19 is generally a mild disease in children, including infants. However, a small proportion develop severe disease requiring ICU admission and prolonged ventilation, although fatal outcome is overall rare. The data also reflect the current uncertainties regarding specific treatment options, highlighting that additional data on antiviral and immunomodulatory drugs are urgently needed.
<br>
<strong>Funding</strong>
ptbnet is supported by Deutsche Gesellschaft für Internationale Zusammenarbeit. |
| first_indexed | 2024-03-07T06:36:25Z |
| format | Journal article |
| id | oxford-uuid:f7d037a4-1ceb-4ed4-af4c-345c2ef865aa |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:36:25Z |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:f7d037a4-1ceb-4ed4-af4c-345c2ef865aa2022-03-27T12:45:34ZCOVID-19 in children and adolescents in Europe: a multinational, multicentre cohort studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f7d037a4-1ceb-4ed4-af4c-345c2ef865aaEnglishSymplectic ElementsElsevier2020Götzinger, FSantiago-García, BNoguera-Julián, ALanaspa, MLancella, LCalò Carducci, FIGabrovska, NVelizarova, SPrunk, POsterman, VKrivec, ULo Vecchio, AShingadia, DSoriano-Arandes, AMelendo, SLanari, MPierantoni, LWagner, NL'Huillier, AGHeininger, URitz, NBandi, SKrajcar, NRoglić, SSantos, MChristiaens, CCreuven, MBuonsenso, DWelch, SBBogyi, MBrinkmann, FTebruegge, MSong, RPfefferle, JZacharasiewicz, ABerger, ABerger, RStrenger, VKohlfürst, DSZschocke, ABernar, BSimma, BHaberlandt, EThir, CBiebl, AVanden Driessche, KBoiy, TVan Brusselen, DBael, ADebulpaep, SSchelstraete, Pptbnet COVID-19 Study Group<strong>Background</strong> To date, few data on paediatric COVID-19 have been published, and most reports originate from China. This study aimed to capture key data on children and adolescents with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection across Europe to inform physicians and health-care service planning during the ongoing pandemic. <br> <strong>Methods</strong> This multicentre cohort study involved 82 participating health-care institutions across 25 European countries, using a well established research network—the Paediatric Tuberculosis Network European Trials Group (ptbnet)—that mainly comprises paediatric infectious diseases specialists and paediatric pulmonologists. We included all individuals aged 18 years or younger with confirmed SARS-CoV-2 infection, detected at any anatomical site by RT-PCR, between April 1 and April 24, 2020, during the initial peak of the European COVID-19 pandemic. We explored factors associated with need for intensive care unit (ICU) admission and initiation of drug treatment for COVID-19 using univariable analysis, and applied multivariable logistic regression with backwards stepwise analysis to further explore those factors significantly associated with ICU admission. <br> <strong>Findings</strong> 582 individuals with PCR-confirmed SARS-CoV-2 infection were included, with a median age of 5·0 years (IQR 0·5–12·0) and a sex ratio of 1·15 males per female. 145 (25%) had pre-existing medical conditions. 363 (62%) individuals were admitted to hospital. 48 (8%) individuals required ICU admission, 25 (4%) mechanical ventilation (median duration 7 days, IQR 2–11, range 1–34), 19 (3%) inotropic support, and one (<1%) extracorporeal membrane oxygenation. Significant risk factors for requiring ICU admission in multivariable analyses were being younger than 1 month (odds ratio 5·06, 95% CI 1·72–14·87; p=0·0035), male sex (2·12, 1·06–4·21; p=0·033), pre-existing medical conditions (3·27, 1·67–6·42; p=0·0015), and presence of lower respiratory tract infection signs or symptoms at presentation (10·46, 5·16–21·23; p<0·0001). The most frequently used drug with antiviral activity was hydroxychloroquine (40 [7%] patients), followed by remdesivir (17 [3%] patients), lopinavir–ritonavir (six [1%] patients), and oseltamivir (three [1%] patients). Immunomodulatory medication used included corticosteroids (22 [4%] patients), intravenous immunoglobulin (seven [1%] patients), tocilizumab (four [1%] patients), anakinra (three [1%] patients), and siltuximab (one [<1%] patient). Four children died (case-fatality rate 0·69%, 95% CI 0·20–1·82); at study end, the remaining 578 were alive and only 25 (4%) were still symptomatic or requiring respiratory support. <br> <strong>Interpretation</strong> COVID-19 is generally a mild disease in children, including infants. However, a small proportion develop severe disease requiring ICU admission and prolonged ventilation, although fatal outcome is overall rare. The data also reflect the current uncertainties regarding specific treatment options, highlighting that additional data on antiviral and immunomodulatory drugs are urgently needed. <br> <strong>Funding</strong> ptbnet is supported by Deutsche Gesellschaft für Internationale Zusammenarbeit. |
| spellingShingle | Götzinger, F Santiago-García, B Noguera-Julián, A Lanaspa, M Lancella, L Calò Carducci, FI Gabrovska, N Velizarova, S Prunk, P Osterman, V Krivec, U Lo Vecchio, A Shingadia, D Soriano-Arandes, A Melendo, S Lanari, M Pierantoni, L Wagner, N L'Huillier, AG Heininger, U Ritz, N Bandi, S Krajcar, N Roglić, S Santos, M Christiaens, C Creuven, M Buonsenso, D Welch, SB Bogyi, M Brinkmann, F Tebruegge, M Song, R Pfefferle, J Zacharasiewicz, A Berger, A Berger, R Strenger, V Kohlfürst, DS Zschocke, A Bernar, B Simma, B Haberlandt, E Thir, C Biebl, A Vanden Driessche, K Boiy, T Van Brusselen, D Bael, A Debulpaep, S Schelstraete, P COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study |
| title | COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study |
| title_full | COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study |
| title_fullStr | COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study |
| title_full_unstemmed | COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study |
| title_short | COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study |
| title_sort | covid 19 in children and adolescents in europe a multinational multicentre cohort study |
| work_keys_str_mv | AT gotzingerf covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT santiagogarciab covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT noguerajuliana covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT lanaspam covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT lancellal covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT calocarduccifi covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT gabrovskan covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT velizarovas covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT prunkp covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT ostermanv covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT krivecu covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT lovecchioa covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT shingadiad covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT sorianoarandesa covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT melendos covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT lanarim covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT pierantonil covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT wagnern covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT lhuillierag covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT heiningeru covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT ritzn covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT bandis covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT krajcarn covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT roglics covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT santosm covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT christiaensc covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT creuvenm covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT buonsensod covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT welchsb covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT bogyim covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT brinkmannf covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT tebrueggem covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT songr covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT pfefferlej covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT zacharasiewicza covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT bergera covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT bergerr covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT strengerv covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT kohlfurstds covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT zschockea covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT bernarb covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT simmab covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT haberlandte covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT thirc covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT biebla covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT vandendriesschek covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT boiyt covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT vanbrusselend covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT baela covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT debulpaeps covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy AT schelstraetep covid19inchildrenandadolescentsineuropeamultinationalmulticentrecohortstudy |